Here are five insights:
1. Dimitri Drone, global deals leader for pharmaceuticals and life sciences at PricewaterhouseCoopers, said Brexit may have a minimal effect on U.S. biotechnology companies, despite some other healthcare companies that may experience challenges obtaining fundraising and regulatory approval.
2. He argues certain pharmaceutical companies may benefit from UK’s exit as the decision may lead to the deterioration of the pound, thereby increasing the relative value of the U.S. dollar.
3. Brexit additionally may not substantially impact hospitals and state providers, and the “modest negative impact” could involve buying opportunities if share price declines persist.
4. Those looking to invest should consider managed healthcare and healthcare facilitates, which are “relatively insulated from the European tumult.”
5. Investors should center on companies including Aetna and HCA Holdings.
More healthcare news:
7 things for ASC leaders to know for Monday — June 27, 2016
9 things to know about GIQuIC
Medicare funds depleting fast; may run out of funds by 2028: 5 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
